- I-SPY COVID will evaluate the impact of cenicriviroc, Otezla®, and Firazyr® on inflammatory response in COVID-19 patients
- Additional candidates from COVID R&D member companies entering platform trials in coming weeks
PR Newswire
SAN FRANCISCO, Aug. 3, 2020